**Background of GPR182 Antibody**
GPR182. a class A G protein-coupled receptor (GPCR), remains an orphan receptor with an unidentified endogenous ligand. It is broadly expressed in endothelial and immune cells, as well as in various tissues, including the liver, intestine, and brain. Research suggests its involvement in angiogenesis, immune regulation, and tumor microenvironment modulation. GPR182 has been linked to cancer progression, particularly in hepatocellular carcinoma, colorectal cancer, and pancreatic ductal adenocarcinoma, where it may influence cell proliferation, migration, and vascular remodeling.
The GPR182 antibody is a critical tool for detecting and localizing GPR182 in experimental models. It enables studies on receptor expression patterns, cellular localization, and functional mechanisms via techniques like immunohistochemistry (IHC), western blotting (WB), and immunofluorescence (IF). Both polyclonal and monoclonal antibodies have been developed, often targeting extracellular or intracellular epitopes to assess membrane-bound or internalized receptor forms.
Current research focuses on elucidating GPR182's signaling pathways, potential ligands, and therapeutic relevance. Its role in regulating chemokine-like functions and cross-talk with other GPCRs highlights its potential as a drug target for cancer or inflammatory diseases. However, the lack of definitive ligand information and pathway characterization underscores the need for further investigation, with GPR182 antibodies remaining indispensable for advancing these studies.